NANOVAC
Latest Information Update: 27 Jan 2022
Price :
$50 *
At a glance
- Originator Intravacc; Leiden University Medical Center
- Class Adjuvants; COVID-19 vaccines; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
- Research Coronavirus infections
Most Recent Events
- 05 Jan 2022 Early research in Coronavirus infections (Prevention) in Netherlands (Intranasal) as of January 2022
- 05 Jan 2022 Preclinical trials in COVID-2019 infections (Prevention) in Netherlands (Intranasal) as of January 2022
- 05 Jan 2022 Intravacc plans a phase I/II trial in COVID-2019 infections (Prevention) at the end of 2022 (Intranasal)